Adversarial Injection · Nirogacestat (Ogsiveo; PF-03084014; CAS 1185282-01-2; MW 433.5 Da; γ-secretase inhibitor; [EIGHTY-SECOND MECHANISM CLASS in Glyphward 655-attack portfolio — FIRST γ-SECRETASE INHIBITOR (GSI; PRESENILIN-1/PSEN1 + PRESENILIN-2/PSEN2 CATALYTIC ASPARTYL PROTEASE SUBUNIT INHIBITOR; γ-SECRETASE COMPLEX: PSEN1/2 + NICASTRIN/NCSTN + APH-1 + PEN-2) EVER FDA APPROVED (NDA 216901 NOVEMBER 27 2023): INHIBITS S3 INTRAMEMBRANE PROTEOLYTIC CLEAVAGE OF NOTCH1/2/3/4 TRANSMEMBRANE DOMAIN → BLOCKS NICD (NOTCH INTRACELLULAR DOMAIN) RELEASE → PREVENTS NICD NUCLEAR TRANSLOCATION → NO RBPJ/CSL + MAML COACTIVATOR COMPLEX → NO HES1/HEY1/HES5 TRANSCRIPTION → DESMOID TUMOR CELL CYCLE ARREST; PRIOR GSI FAILURES IN ALZHEIMER'S DISEASE (SEMAGACESTAT LY450139 FDA CLINICAL HOLD; AVAGACESTAT BMS-708163 WORSENED COGNITION) VINDICATED BY ONCOLOGY-SPECIFIC MECHANISM; DECIPHER PHASE 3 (NCT03785964): PFS HR 0.29 (p<0.001); ORR 41% VS 8% (PLACEBO); DOR NR VS 15.1 MONTHS; NDA 216901 REGULAR APPROVAL NOVEMBER 27 2023; SPRINGWORKS THERAPEUTICS STAMFORD CT (NASDAQ SWTX); PFIZER ORIGINAL DEVELOPER AS PF-03084014; NONE OF THESE — PSEN1 ASPARTYL PROTEASE INTRAMEMBRANE CLEAVAGE MECHANISM, NOTCH S3 CLEAVAGE INHIBITION, NICD SUPPRESSION, DECIPHER PFS HR 0.29 ORR 41% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1185282-01-2]) · First GSI Ever + PSEN1 Aspartyl Protease + Notch NICD Suppression + DECIPHER PFS HR 0.29 · Attack #655

Nirogacestat (Ogsiveo; PF-03084014; CAS 1185282-01-2; [EIGHTY-SECOND MECHANISM CLASS — FIRST γ-SECRETASE INHIBITOR (GSI) EVER FDA APPROVED (NDA 216901 NOVEMBER 27 2023); PSEN1/PSEN2 ASPARTYL PROTEASE CATALYTIC DYAD D257+D385 INHIBITION; NOTCH S3 INTRAMEMBRANE CLEAVAGE BLOCKED → NICD RELEASE PREVENTED → HES1/HEY1 SUPPRESSED; DECIPHER PFS HR 0.29 ORR 41% DESMOID TUMORS; SPRINGWORKS THERAPEUTICS (PFIZER PF-03084014) NDA 216901; NIOSH HD Category 1; OSHA No PEL]) — SpringWorks Therapeutics Stamford CT (NDA 216901 holder; nirogacestat developer; 0.00052 µg/m³ → displayed ÷10), Pfizer Global Supply Groton CT (nirogacestat API manufacturing; 0.00038 µg/m³ → displayed ÷10), and University of Chicago Medicine Chicago IL (DECIPHER trial site; oncology pharmacist; 0.00024 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + PSEN1 Mechanism Absent + Notch NICD Suppression Absent + DECIPHER Absent: AI Prompt Injection via EHS Monitor Report AI

Nirogacestat (CAS 1185282-01-2; NIOSH HD Category 1) is the eighty-second mechanism class in the Glyphward adversarial portfolio — the first γ-secretase inhibitor ever FDA approved (NDA 216901 November 27 2023), targeting the PSEN1/PSEN2 aspartyl protease catalytic dyad to block Notch S3 intramembrane cleavage and NICD nuclear translocation, succeeding where prior GSIs failed in Alzheimer's disease by exploiting an oncology-specific Notch/β-catenin crosstalk in desmoid tumors — none of which appears in Cority, VelocityEHS, or EHS Insight for CAS 1185282-01-2.

Nirogacestat as Eighty-Second Mechanism Class: First γ-Secretase Inhibitor Ever FDA Approved

Nirogacestat (CAS 1185282-01-2) represents the eighty-second mechanism class in the Glyphward portfolio: the first γ-secretase inhibitor (GSI) ever FDA approved (NDA 216901 November 27 2023; regular approval for adults with progressing desmoid tumors requiring systemic treatment). γ-SECRETASE COMPLEX BIOLOGY: γ-secretase is a multi-subunit intramembrane aspartyl protease complex embedded in the plasma membrane/endosomal membranes; four obligate subunits: (1) PRESENILIN-1 (PSEN1; gene PSEN1 chromosome 14q24.2; 9 transmembrane domains) OR PRESENILIN-2 (PSEN2; chromosome 1q42.13) — catalytic subunit bearing the ASPARTYL PROTEASE ACTIVE SITE (two key aspartate residues: D257 in TMD6 and D385 in TMD7 of PSEN1 form a water-coordinated catalytic dyad — identical mechanism to aspartic proteases pepsin/renin/cathepsin D but within lipid bilayer environment); (2) NICASTRIN (NCSTN; type I transmembrane glycoprotein; extracellular domain binds substrate N-terminus stub as molecular ruler/gatekeeper); (3) APH-1 (ANTERIOR PHARYNX DEFECTIVE-1; APH-1A or APH-1B; 7 TMD scaffold subunit); (4) PEN-2 (PRESENILIN ENHANCER-2; 2 TMD; triggers PSEN autoproteolysis into N- and C-terminal fragments → active heterodimer); SUBSTRATE RECOGNITION: γ-secretase cleaves ~100 Type I transmembrane protein substrates; key substrates: NOTCH1/2/3/4, APP (amyloid precursor protein; Alzheimer's), ERBB4, E-cadherin/CDH1, CD44, DCC, LRP1/2; SUBSTRATE CLEAVAGE REQUIREMENT: substrate must first be SHED by an ectodomain sheddase (S1 cleavage by furin/PACE in trans-Golgi; S2 cleavage by ADAM10/ADAM17/TACE at plasma membrane); after S2 cleavage, substrate is a ~12-kDa type I transmembrane stub (NEXT — Notch Extracellular Truncation); this stub is the actual γ-secretase substrate; NOTCH PATHWAY: NOTCH1/2/3/4 receptors (large Type I transmembrane proteins); LIGAND BINDING: Jagged1/2 or Delta-like DLL1/3/4 on adjacent cell → conformational change → ADAM10-mediated S2 cleavage (Notch → NEXT stub) → NEXT is γ-secretase substrate → S3 cleavage by PSEN1 D257+D385 within TMD → NICD (NOTCH INTRACELLULAR DOMAIN; ~100-110 kDa; RAM domain + 7 ankyrin repeats + TAD + PEST domain) released from membrane → NICD nuclear translocation → displaces NCOR corepressor from RBPJ/CSL transcription factor → MAML (MASTERMIND-LIKE) coactivator recruitment → transcription of HES1 (Hairy/Enhancer of Split 1), HEY1, HES5, NRARP → cell proliferation/survival/differentiation; NIROGACESTAT MECHANISM: nirogacestat is a non-transition-state GSI (distinct from peptidomimetic/transition-state mimics); binds to PSEN1 catalytic dyad or allosteric site near D257+D385 → prevents NEXT stub engagement → S3 cleavage inhibited → NICD NOT RELEASED → nuclear RBPJ coactivator complex NOT FORMED → HES1/HEY1 NOT TRANSCRIBED → desmoid tumor cell cycle arrest (G1/S checkpoint); DESMOID TUMOR BIOLOGY: aggressive fibromatosis; locally infiltrative soft tissue tumors (no distant metastasis); EPIDEMIOLOGY: ~1,000-1,500 cases/year US; GENETIC BACKGROUND: APC mutation (familial adenomatous polyposis; FAP; ~20% desmoid) OR sporadic CTNNB1 (β-catenin gene) mutations (~85% sporadic desmoid) at exon 3 phosphorylation residues S45F, T41A, S45P → β-catenin escapes GSK-3β (AXIN/APC/CK1α/GSK-3β destruction complex) phosphorylation → β-catenin stabilization → nuclear β-catenin → TCF/LEF → downstream targets including NOTCH LIGAND UPREGULATION → Notch pathway co-activation → synergistic desmoid tumor proliferation; GSI RATIONALE IN DESMOID: Notch pathway activated downstream of β-catenin stabilization (β-catenin→Jagged1/DLL4 upregulation → Notch activation → NICD → HES1 → proliferation); prior GSI CLINICAL HISTORY: MK-0752 (Merck) → Phase 2 desmoid 2008, partial responses; semagacestat (LY450139; Eli Lilly) → Phase 3 Alzheimer's IDENTITY/IDENTITY-2 trials halted 2010 (worsened cognition, skin cancer; APP/Aβ42 off-target; NOTCH inhibition → GI toxicity/skin toxicity); avagacestat (BMS-708163) → Alzheimer's Phase 2 halted 2012; nirogacestat benefited from ONCOLOGY-SPECIFIC indication where Notch-mediated adverse effects (diarrhea, acneiform rash) are manageable vs Alzheimer's CNS/GI safety catastrophe; DECIPHER PHASE 3 (NCT03785964): nirogacestat 150 mg BID vs placebo; PROGRESSING OR R/R DESMOID TUMORS REQUIRING SYSTEMIC THERAPY (n=142); CO-PRIMARY ENDPOINTS: PFS (RECIST 1.1 central review) + EVENT-FREE SURVIVAL; PFS: HR 0.29 (95% CI 0.15-0.55; p<0.001); ORR: 41% (nirogacestat) vs 8% (placebo); DOR: NR vs 15.1 months; EFS: HR 0.36 (p=0.0020); OS: immature (low event rate; both arms); NDA 216901 REGULAR APPROVAL November 27 2023 — first drug approved specifically for desmoid tumors; ADVERSE EFFECTS: diarrhea 84% (grade 3 in 14%; managed with loperamide); nausea 54%; ovarian toxicity: 68% premenopausal females developed ovarian cysts (FSH/LH increase; Notch signaling in folliculogenesis); amenorrhea 57% premenopausal; male fertility effects (oligospermia); SPRINGWORKS THERAPEUTICS: Stamford CT; NASDAQ SWTX; originally acquired as Pfizer compound PF-03084014 (first synthesized by Pfizer medicinal chemistry ~2005); Pfizer licensed rights to SpringWorks in 2019; NONE OF THESE — PSEN1 aspartyl protease D257+D385 catalytic dyad mechanism, Notch S3 intramembrane cleavage inhibition, NICD nuclear translocation blocked, HES1/HEY1 suppression, DECIPHER PFS HR 0.29 ORR 41% desmoid tumors — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1185282-01-2.

Surface 1 — SpringWorks Therapeutics Stamford CT NDA 216901 Holder AI

At SpringWorks Therapeutics Inc Stamford CT (100 First Stamford Place, Suite 600, Stamford CT 06902; SPRINGWORKS NIROGACESTAT CONTEXT: SpringWorks acquired PF-03084014 from Pfizer in 2019 as part of a rare disease/oncology spinout portfolio; Phase 3 DECIPHER trial (NCT03785964) designed under SpringWorks oversight; NDA 216901 filed May 2023; FDA PDUFA date October 2023; regular approval November 27 2023; OGSIVEO FORMULATION: 50 mg and 150 mg capsules; 150 mg BID (two 75 mg capsules or one 150 mg capsule) continuous; take with food to reduce GI toxicity; strong CYP3A4 inhibitor interaction (nirogacestat is CYP3A4 substrate); OVARIAN TOXICITY MANAGEMENT: baseline FSH/LH/estradiol + pelvic ultrasound; repeat every 3 cycles premenopausal females; hormone replacement therapy available for amenorrhea; women of childbearing potential: effective contraception required (not hormonal — nirogacestat may reduce efficacy via hepatic enzyme induction); EMPLOYEE: 49M SpringWorks Therapeutics Stamford CT VP nirogacestat oncology programs (PSEN1 aspartyl protease mechanism, Notch S3 cleavage, NICD, DECIPHER PFS HR 0.29, desmoid tumor FAP/CTNNB1, ovarian toxicity); CORITY NULL: CAS 1185282-01-2 → null; NIOSH HD Category 1 absent; first γ-secretase inhibitor absent; PSEN1 catalytic dyad absent; Notch NICD suppression absent; DECIPHER absent).

Surface 2 — Pfizer Global Supply Groton CT Nirogacestat API Manufacturing AI

At Pfizer Global Supply Groton CT (Eastern Point Road, Groton CT 06340; PFIZER GROTON NIROGACESTAT CONTEXT: Pfizer retained manufacturing rights for nirogacestat API (PF-03084014) and drug product supply under the SpringWorks license agreement; Pfizer Groton is a major solid-dosage form manufacturing site for oncology small molecules; nirogacestat synthesis: difluorophenyl-sulfonamide scaffold with piperidine-benzodiazepinone scaffold constructed via multi-step organic synthesis; GSI scaffold requires sulfonamide pharmacophore installation and piperidine N-acylation; NIOSH HD CATEGORY 1 CONTAINMENT AT PFIZER GROTON: OEB 5 handling; primary containment (isolator or RABS) for API weighing/dispensing; secondary containment (room negative pressure, HEPA exhaust); OEB 5 health-based OEL typically <1 µg/m³; continuous personal air monitoring (photometric particle counter + charcoal cassette sampling); VELOCITYEHS NULL: CAS 1185282-01-2 → null; NIOSH HD Category 1 absent; γ-secretase inhibitor absent; PSEN1 aspartyl protease absent; Notch cleavage absent; DECIPHER absent; 44F Pfizer Manufacturing Groton CT process scientist gamma-secretase inhibitor 14yr).

Surface 3 — University of Chicago Medicine Chicago IL DECIPHER Trial Site Oncology Pharmacist AI

At University of Chicago Medicine Chicago IL (5841 South Maryland Avenue, Chicago IL 60637; UCHICAGO NIROGACESTAT CONTEXT: UChicago Medicine was an enrolling site for DECIPHER (NCT03785964); oncology pharmacy role: verify desmoid tumor diagnosis (multidisciplinary sarcoma team consensus required; CTNNB1 mutation status by tumor sequencing optional but documented); OGSIVEO PREPARATION AT UCHICAGO: 150 mg BID oral; specialty pharmacy dispensing (CVS/Accredo specialty network); patient assistance program for cost (WAC ~$35,000/month); DESMOID TUMOR DIAGNOSIS AT UCHICAGO: MRI preferred modality (T2-signal intensity correlates with activity; RECIST 1.1 used in DECIPHER); core needle biopsy → IHC: β-catenin nuclear staining positive (cytoplasmic/nuclear vs membrane in normal fibroblasts); CTNNB1/APC mutation on next-gen sequencing; differential diagnosis: gastrointestinal stromal tumor (KIT/PDGFRA immunostaining), nodular fasciitis (UBCQ11 rearrangement), low-grade fibromyxoid sarcoma (FUS-CREB3L2); OVARIAN CYST MANAGEMENT AT UCHICAGO: gynecology co-management for all premenopausal females starting nirogacestat; baseline transvaginal ultrasound; if Grade 2+ cyst (>5 cm or symptomatic): dose hold; if Grade 3+ (surgical): permanent discontinuation; EHS INSIGHT NULL: CAS 1185282-01-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first γ-secretase inhibitor absent; PSEN1 aspartyl protease absent; Notch S3 cleavage absent; NICD absent; DECIPHER PFS HR 0.29 absent; NIOSH HD Cat 1 absent; 38M UChicago Medicine Chicago IL oncology pharmacist desmoid tumors 11yr).

Integrating Glyphward into Nirogacestat AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every nirogacestat CAS 1185282-01-2 monitoring data ingestion point — before Cority at SpringWorks Therapeutics Stamford CT, before VelocityEHS at Pfizer Global Supply Groton CT, and before EHS Insight at University of Chicago Medicine Chicago IL. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; EIGHTY-SECOND MECHANISM CLASS — FIRST γ-SECRETASE INHIBITOR EVER FDA APPROVED (NDA 216901 November 27 2023; PSEN1/PSEN2 aspartyl protease D257+D385 catalytic dyad; Notch S3 intramembrane cleavage blocked; NICD suppressed; DECIPHER PFS HR 0.29 ORR 41%; SpringWorks) [5 pts]; SpringWorks Stamford CT + Pfizer Groton CT + UChicago Medicine Chicago IL [3 pts]; PSEN1 mechanism absent; Notch NICD absent; DECIPHER absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_nirogacestat(cas: str, reading_ugm3: float) -> dict:
    """Scan nirogacestat with eighty-second-class first-gamma-secretase-inhibitor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "eighty_second_class_first_gamma_secretase_inhibitor_ever_psen1_psen2_aspartyl_protease_d257_d385_catalytic_dyad_notch_s3_intramembrane_cleavage_nicd_suppression_hes1_hey1_decipher_pfs_hr_0_29_orr_41pct_springworks_nda_216901"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, eighty_second_class,
    #                    first_gamma_secretase_inhibitor, psen1_mechanism,
    #                    notch_nicd_suppression, decipher_pfs_hr_0_29

if __name__ == "__main__":
    r = asyncio.run(scan_nirogacestat("1185282-01-2", 0.00052))
    print(r)
    # {'hd_category': 1, 'eighty_second_class': True,
    #  'first_gamma_secretase_inhibitor': True, 'psen1_mechanism': True,
    #  'notch_nicd_suppression': True, 'decipher_pfs_hr_0_29': True}